[The effect of etiopathogenetic therapy of COVID-19 on the severity of the disease: results of a multicenter double-blind placebo-controlled randomized trial].
V V NikiforovV A PetrovA A StremoukhovM G AvdeevaY G ShvartsI E KravchenkoI V NikolaevaS E UshakovaO N BelousovaN A EreminaS V TeplykhEkaterina MelnikovaN E KostinаPublished in: Terapevticheskii arkhiv (2023)
Raphamin reduces the risk of progression to a more severe degree of the COVID-19 and significantly shortens the duration of clinical symptoms.